AndhraNews.net
Home » Features » Health » Cardiac Resynchronization Therapy

Cardiac Resynchronization Therapy


Cardiac Resynchronization Therapy is a type of pacemaker that can pace both the septal and lateral walls of the left ventricle. By pacing both sides of the left ventricle, the pacemaker can resynchronize a heart whose opposing walls do not contract in synchrony, which occurs in approximately 25-50% of heart failure patients.

Cardiac Resynchronization Therapy (CRT) is also called biventricular pacemaker.

Cardiac Resynchronization Therapy in News

COR Medical Technologies Updates and Expands the American Journal of Cardiology Heart Failure Resource Center

BIOTRONIK Iforia Is the World's First DF4 ICD/CRT-D Series Approved for MRI
BIOTRONIK, the leading manufacturer of cardiovascular medical technology celebrating its 50th anniversary this year, gains market approval (CE-approval) for the most advanced ICD/CRT-D (cardioverter-defibrillator/cardiac resynchronization therapy defibrillator) series. Iforia is the world's first DF4 ICD/CRT-D series approved for MRI (magnetic resonance imaging)

BIOTRONIK Ilesto 7 ICD/CRT-D Series With ProMRI(R) Technology Gains CE Approval
BIOTRONIK, the leading manufacturer of cardiovascular medical technology that is celebrating its 50th anniversary in 2013, announced today that the Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D) series has received CE approval

BIOTRONIK Launches Implantable BioMonitor(R) -- Highest Precision in Monitoring Arrhythmias
BIOTRONIK, a leading manufacturer of medical technology, today announced the European market release of BioMonitor®, a unique implantable cardiac device designed for the highly accurate and reliable monitoring and management of patients with atrial fibrillation (AF) or unexplained syncope.

BIOTRONIK Presents World's Broadest Portfolio of Cardiac Devices Approved for MR Scans at Cardiostim 2012
BIOTRONIK's innovative new ProMRI® technology, which for the first time allows implantable cardiac defibrillator (ICD) and heart failure patients to undergo life-saving magnetic resonance imaging (MRI) scans, is scheduled to be showcased at the Cardiostim 2012, 18th World Congress in Nice, France, from June 13-16.

BIOTRONIK Presents World's First ICD, CRT-D and CRT-P Devices With ProMRI(R) Technology at Heart Rhythm 2012
BIOTRONIK, a leading manufacturer of innovative medical technology, has developed the world's first implantable cardiac defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and cardiac resynchronization therapy pacemaker (CRT-P) with ProMRI® technology

BIOTRONIK Evia HF-T, World's First MRI-Approved CRT Pacemaker
BIOTRONIK, a leading manufacturer of medical devices featuring innovative technology, announced today the European market release of the new Evia HF-T pacemaker series. Evia HF-T is the first cardiac resynchronization therapy (CRT-P) device approved for use in an MRI environment(1)

New BIOTRONIK ICD and CRT-D Series Gives Patients First-Ever Access to MR Scans
BIOTRONIK, a leading manufacturer of innovative medical technology, announced today the European full market release of the new Lumax 740 ICDs (implantable cardiac defibrillators) and CRT-Ds (cardiac resynchronization therapy defibrillators) in the European market

FDA Approves BIOTRONIK Next Generation ICDs and CRT-Ds
BIOTRONIK, a leading manufacturer of innovative medical technology, has received FDA approval of its new Lumax 740 implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds)

BIOTRONIK REPLACE Study Establishes New Benchmarks for CIED Replacement
The BIOTRONIK sponsored REPLACE study1,2 is the first prospective, multicenter trial to examine a broad range of complications related to replacement of all companies’ cardiovascular implantable electronic devices (CIED) which includes both pacemakers and ICDs (implantable cardiac defibrillators)

Missouri Baptist Medical Center Physicians Are First in Missouri to Implant New Heart Failure Device
Cardiologists at Missouri Baptist Medical Center, one of Missouri's leading heart centers, were the first in the state to implant a new type of cardiac resynchronization therapy defibrillator (CRT-D), designed to better manage patients with heart failure

BIOTRONIK Home Monitoring® Detects Atrial High-Rate Events Associated With Increased Risks for Heart Failure Patients
BIOTRONIK announced today the publication of “Detection of atrial high-rate events by continuous Home Monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population” in Europace by Dr. Nesan Shanmugam et al

BIOTRONIK Introduces the World’s First and Only Implantable Defibrillators Eligible for Magnetic Resonance Imaging
BIOTRONIK, a leading manufacturer of innovative medical technology, announced the first implantations of the new Lumax 740 implantable cardiac defibrillators—the world’s first and only ICDs eligible for use with magnetic resonance imaging

BIOTRONIK Presents New Economic Model: Remote Monitoring Reduces Hospital Workload and Healthcare Costs for Patients with Cardiac Implantable Electrical Devices
For the first time, an economic model has been presented that estimates the burden of calendar-based in-office follow-up for patients with cardiac implantable electrical devices (CIED) in Germany and the United Kingdom (UK)

New BIOTRONIK Home Monitoring® Quick View Report Enhances Efficiency of Cardiac Device Patient Management
BIOTRONIK, a worldwide leader in manufacturing cardiac medical devices and pioneer of remote patient management solutions, today announced the introduction of a new online Quick View report designed to deliver even greater efficiency when managing patients using BIOTRONIK Home Monitoring® technology.

BIOTRONIK Selectra Lead Introducer System Gets Strong Reviews in First Cases
The BIOTRONIK Selectra CS Lead Introducer System has received overwhelmingly positive reviews in the first device implantation cases across the US and Europe. Physicians are unanimous that Selectra delivers a significant advancement in lead placement systems for cardiac resynchronization therapy (CRT) devices.

BIOTRONIK Announces Japanese Market Release for Renamic: Next-Generation Programmer for Implantable Cardiac Devices
BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, announced today the Japanese market release of Renamic, their next-generation programmer for implantable devices used in cardiac rhythm management (CRM).

St. Jude Medical Highlights Leading Technologies and Physician Training at Cardiac Arrhythmia Congresses in Japan
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, is pleased to again participate in the Asia-Pacific Heart Rhythm Society Scientific Session (APHRS), which is being held this year in conjunction with the Japanese Heart Rhythm Society (JHRS) and the Japanese Society of Electrocardiology (JSE) in Fukuoka, Japan.

St. Jude Medical Launches the Industry's First Quadripolar Pacing System in India
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the approval of the industry’s first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds) in India

BIOTRONIK Announces European Market Approval of Selectra: Advanced New Telescopic CRT Lead Delivery System
BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced the European market approval of the Selectra left ventricular lead delivery system.

Comment on this story

Share